$30.36−1.47 (−4.62%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Ideaya Biosciences (IDYA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~67.3%/yr (FY21→FY25), net margin −52.0%. Worth your attention in FY25: Share count (+151.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲3024.4%
218.7
FY21→FY25CAGR +67.3%/yr
Net income ($M)▲58.6%
−113.7
FY21→FY25CAGR —
Free cash flow ($M)▲70.8%
−73.5
FY21→FY25CAGR —
Diluted EPS▲61.9%
−1.28
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+151.0%
35.3mn → 88.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$2.4M
−38.6% YoY in FY25 · 1.1% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-52¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -52.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 36,535.0 | 218,710.0 | 7,000.0 | 23,385.0 | 50,931.0 | 27,941.0 | ▲3024.4% | +67.3% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 36,535.0 | 218,710.0 | 7,000.0 | 23,385.0 | 50,931.0 | 27,941.0 | ▲3024.4% | +67.3% |
Research & development | 412,590.0 | 314,704.0 | 294,673.0 | 129,508.0 | 89,536.0 | 58,158.0 | ▲6.8% | +52.5% |
Selling, general & admin | 86,982.0 | 63,319.0 | 39,302.0 | 28,306.0 | 23,897.0 | 20,051.0 | ▲61.1% | +33.3% |
Total operating expenses | 499,572.0 | 378,023.0 | 333,975.0 | 157,814.0 | 113,433.0 | 78,209.0 | ▲13.2% | +48.3% |
Operating incomefeeds ROC rank | −463,037.0 | −159,313.0 | −326,975.0 | −134,429.0 | −62,502.0 | −50,268.0 | ▲51.3% | — |
Other income, net | 44,500.0 | 45,615.0 | 52,498.0 | 21,468.0 | 0.0 | 506.0 | — | — |
Pretax income | −418,537.0 | −113,698.0 | −274,477.0 | −112,961.0 | −62,502.0 | −49,762.0 | ▲58.6% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −420,013.0 | −113,698.0 | −274,477.0 | −112,961.0 | −58,655.0 | −49,762.0 | ▲58.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −4.46 | −1.28 | −3.36 | −1.96 | −1.42 | −1.41 | ▲61.9% | — |
Diluted shares (mn) | 102.94 | 88.49 | 81.68 | 57.52 | 41.44 | 35.25 | ▲8.3% | +25.9% |
| Margins | ||||||||
Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −1267.4% | −72.8% | −4671.1% | −574.9% | −122.7% | −179.9% | ▲4598.2pp | +107.1pp |
Net margin1st pct in Healthcare | −1149.6% | −52.0% | −3921.1% | −483.0% | −115.2% | −178.1% | ▲3869.1pp | +126.1pp |
† TTM = trailing four quarters through 2026-09-30.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Ideaya Biosciences' revenue last fiscal year?
Ideaya Biosciences reported revenue of $218.7M in fiscal 2025, up 3024.4% from fiscal 2024.
What was Ideaya Biosciences' net income?
Ideaya Biosciences reported net income of −$113.7M in fiscal 2025, a net margin of −52.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

